Printer Friendly

'FRENCH ABORTION PILL,' RU486 IN METASTATIC BREAST CANCER TRIAL

 LONG BEACH, Calif., Nov. 17 /PRNewswire/ -- RU486 (Mifepristone), a drug that recently gained notoriety as the "French abortion pill," will be the subject of an FDA approved Phase II trial being conducted at Long Beach Memorial Medical Center, to determine its affect on metastatic breast ca ?


This is the only trial of its kind in the United States and is a joint project of the Long Beach Memorial Cancer Institute and the Memorial Breast Center. Other trials are ongoing in Canada and France.
 Physicians at the Memorial Breast Center are seeking to enroll 40 women with limited criteria for eligibility. Women eligible for the trial will have a measurable metastatic mass, and will have previously been treated with at least one other hormone therapy that responded favorably prior to failing. Women cannot be pregnant and all premenopausal women will be subject to a pregnancy test.
 "Mifepristone (RU486) seems to have some promising activity against breast cancer, especially in cancer that had responded to hormonal manipulation in the past," said Dr. John Link, medical director of the Memorial Breast Center. "The potential exists that this could give a significant and lasting remission."
 The trial is not randomized. All women will be given the actual drug. Past trials have proven that RU486 has much milder side effects than traditional chemotherapy, including nausea and vomiting. Fatigue and a rash are also potential side effects, but are rare.
 Link pointed out that RU486 originally was never intended as an "abortion pill," and actually has many possible applications. "Drugs don't have social agendas," he said.
 More women will die from breast cancer this year than any other form of cancer other than lung cancer. It is potentially curable if diagnosed and treated early, but there is no known cure as yet for metastatic breast cancer.
 -0- 11/17/93
 /CONTACT: Ron Yukelson, 310-933-2853/


CO: Long Beach Memorial Medical Center ST: California IN: HEA SU:

JB-EH -- LA015 -- 5477 11/17/93 12:08 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 17, 1993
Words:328
Previous Article:C O R R E C T I O N -- IV VENTURES, LTD.; INTILE DESIGNS, INC./
Next Article:RAYTHEON ENGINEERS & CONSTRUCTORS TO BUY EBASCO PRINCIPAL OPERATING ASSETS FOR $210 MILLION
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters